DEADLINES

Young Investigator Travel Awards
FRIDAY, MARCH 29, 2013

Abstract Submission
MONDAY, APRIL 15, 2013

Early Registration
FRIDAY, APRIL 19, 2013

Congress President: Prof. Dr. Rolf D. Issels MD, PhD

Sponsored by the International Association for Hyperthermic Oncology
and its member organizations:

ESHO: European Society for Hyperthermic Oncology

With the welcome participation of the IAH: Interdisziplinäre Arbeitsgruppe
Hyperthermie der Deutschen Krebsgesellschaft
Abstract Submission
The Meeting of the European Society for Hyperthermic Oncology (ESHO) is using an electronic abstract submission process. All abstracts must be submitted electronically, using the online abstract submission form of the ESHO2013 website www.esho2013.org.

Abstract Content and Format
All abstracts must be scientific in nature and address an appropriate topic of discussion without inclusion of commercial messages or inappropriate references to specific products, services, or commercial concerns.

All abstracts must be 250 words in length and submitted in English. Tables, graphs, and structural formulae may not be included, although simple mathematical formulae are acceptable.

Abstract Categories
All abstracts must be submitted within the Clinical, Biological and Engineering/Physics categories listed for the ESHO 2013 meeting. Each submitter must identify up to three (minimum of one) appropriate abstract categories as part of their submission and rank them in order of preference. Do visit www.esho2013.org to view the categories.

Abstract Submission Deadline
The deadline for abstract submission to the ESHO 2013 Congress:

Monday, April 15, 2013: 18.00 hours (CET).

Venue and Registration
The ESHO 2013 Congress will be held at the Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany. All presenters at the ESHO 2013 Congress are expected to register for the meeting separately, using the ESHO 2013 Congress Registration on the ESHO 2013 website.

Registration Deadlines
Deadline for early registration:

Friday, April 19, 2013

Registration fees

<table>
<thead>
<tr>
<th>Category and payment</th>
<th>by April 19, 2013</th>
<th>from April 19, 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participant</td>
<td>450 €*</td>
<td>550 €</td>
</tr>
<tr>
<td>Member (ESHO, IAH, STM)</td>
<td>350 €</td>
<td>400 €</td>
</tr>
<tr>
<td>Students</td>
<td>150 €**</td>
<td>200 €</td>
</tr>
<tr>
<td>Non-Exhibiting industry</td>
<td>1.000 €</td>
<td>1.250 €</td>
</tr>
<tr>
<td>Accompanying person</td>
<td>100 €</td>
<td>150 €</td>
</tr>
<tr>
<td>Congress dinner</td>
<td>50 €*</td>
<td>75 €</td>
</tr>
</tbody>
</table>

*For participant: reduced fee including one year ESHO-Membership and one year free subscription of The International Journal of Hyperthermia.

**For students: reduced fee including one year ESHO-Membership and one year free electronic access of The International Journal of Hyperthermia.

For membership information please visit www.esho.info.
Scientific Abstract Categories

Engineering/Physics
- Non-invasive Thermometry
- Invasive Thermometry
- Hyperthermia Devices
- Radiofrequency
- Microwave
- High Intensity Focused Ultrasound (technical)
- Applicator Development
- Superficial Applicators
- Deep Heating Applicators
- Hyperthermia Treatment Planning
- Interstitial Hyperthermia Technology
- EM Technology for Non-thermal Therapy

Clinic
- Nanotherapy
- High Intensity Focussed Ultrasound (clinical)
- Whole Body Hyperthermia
- Hyperthermic Intrapерitoneal Chemotherapy (HiPEC)
- Isolated Limb Perfusion (ILP)
- Non-thermal Therapy
- Thermal Ablation
- Cervical Cancer
- Breast Cancer
- Rectal Cancer
- Prostate Cancer
- Head and Neck Malignancies
- Pancreatic Cancer
- Sarcomas
- Other Tumor Entities
- Whole Body Hyperthermia and Chemotherapy
- Non-thermal Therapy

Biology
- Tumor Physiology
- Vascular Based Approaches
- Hypoxia
- Cell Signaling Pathways
- Synthetic Lethality
- Tumor Immunology
- Heat Shock Proteins (HSP)
- DNA-Repair
- Thermal Enhancement
- Thermal Dose
- Nanoparticles
- Dendritic Cell Vaccination
- Thermosensitive Liposomes (TSL)
- Non-thermal EM-effects
- Immune Effector Cells

Young Investigator Travel Awards

The ESHO will provide five awards to encourage the participation of young investigators at the congress. Awardees are selected during the meeting by the ESHO award committee. The award committee will evaluate the quality of work (scientific) and presentation (clarity, skills) or poster. Applicants must in addition to the abstract submission complete the application form for Young Investigator Travel Award on the ESHO 2013 website.

Please note the criteria for submitting a Young Investigator Travel Award. The application must be supported by the department chair. Please ensure that the section describing the applicant’s current training program describes how the program relates to hyperthermia.

Application Criteria for Young Investigator Travel Awards

1. A person may apply for a Young Investigator Travel Award regardless of current degree, as long as he/she is working towards a higher degree (e.g. PhD, MD, or DVM) less than three years since receiving a post-graduate degree.

2. The application must be completed and signed by the institution’s department chair.

3. The applicant must submit an abstract via online submission.

4. Each applicant must be a ESHO or STM Member, or have membership application pending.

Application Deadline

The deadline for submission of the Young Investigator Travel Award Application is:

**Friday, March 29, 2013: 18.00 hours (CET).**

Applications received after this date will not be considered.

Submission Instructions

Instructions will be provided on the website www.esho2013.org
LOCATION AND CONTACT

University of Munich Hospital
Campus Grosshadern

Marchioninistraße 15
81377 Munich

Secretary: 0049-89-7095 4768
martina.lahm@med.uni-muenchen.de

www.klinikum.uni-muenchen.de

The venue is easily accessible by public transport (travel time about 15 min. from the city center, subway line U6).

“Join us in Munich for the 28th Annual Meeting of the ESHO on Hyperthermic Oncology 2013. We will conduct a new exploration – into new developments from bench to bedside in hyperthermia.”

Rolf D. Issels, MD, PhD